|
[1] Jone PN, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association[J].Circulation, 2024, 150(23): 481-500.
[2] Kuo HC. Diagnosis, progress, and treatment update of
Kawasaki disease[J].Int J Mol Sci, 2023, 24(18):16.
[3] 陕西省川崎病诊疗中心/陕西省人民医院儿童病院,国家儿童医学中心/首都医科大学附属北京儿童医院,上海交通大学医学院附属儿童医院.中国儿童川崎病诊疗循证指南(2023年)[J].中国当代儿科杂志,2023, 25(12): 1198-1210.
[4] Goel AR, Yalcindag A. An update on Kawasaki disease[J].Curr Rheumatol Rep, 2024,27(1):4.
[5] Zhao J, Ma Y, Xin L, et al. Impact of
intravenous immunoglobulin treatment on peripheral blood cells in children with
Kawasaki disease complicated with coronary artery lesion[J].Ital J Pediatr, 2025,51(1):44.
[6] Jone PN, Tremoulet A, Choueiter N.Update on
diagnosis and management of kawasaki disease: a
scientific statement from the american heart association[J]. Circulation, 2024,150(23):e481-e500.
[7] Burns JC. The etiologies of
Kawasaki disease[J].J Clin Invest, 2024,134(5):e176938.
[8] Wang H, Shimizu C, Bainto E, et al. Subgroups of children with Kawasaki disease: a data-driven cluster analysis[J].Lancet Child Adolesc Health, 2023,7(10):697-707.
[9] Noval RM, Kocatürk B, Franklin BS, et al. Platelets in Kawasaki disease: mediators of vascular inflammation[J].Nat Rev Rheumatol, 2024,20(8):459-472.
[10] Du Y, Lee PY. At the heart of treating kawasaki disease: the search for new approaches to prevent coronary artery aneurysms[J].Arthritis Rheumatol, 2023,75(2):149-152.
[11] Tang Y, Ding C, Xu Q, et al. Prediction nomogram for coronary artery aneurysms at one
month in Kawasaki disease[J].Ital J Pediatr, 2023,49(1):146.
[12] Yang C, Yang Y, Cao S, et al. Kawasaki disease coronary artery lesions prediction with
monocyte-to-high-density lipoprotein ratio[J].Pediatr Res, 2023,94(1):246-251.
[13] Day-lewis M, Son MBF, Lo MS. Kawasaki disease: contemporary
perspectives[J].Lancet Child Adolesc
Health, 2024,8(10):781-792.
[14] Efrati S, Averbukh M, Berman S,et al. N-Acetylcysteine ameliorates lithium-induced renal failure in rats[J].Nephrol Dial Transplant, 2005,20(1):65-70.
[15] Xie Z, Huang Y, Li X, et al. Atlas of circulating immune cells in Kawasaki disease[J].Int Immunopharmacol, 2022,102:108396.
[16] Wang S, Qian G, Liu Y, et al. Kawasaki disease: insights into the roles
of T cells[J].Front Immunol, 2025,16:1582638.
[17] Shuai S, Zhang H, Zhang R, et al. Prediction of coronary artery lesions based on C-reactive protein levels in children with Kawasaki disease: a retrospective cohort study[J].J Pediatr (Rio J), 2023,99(4):406-412.
[18] Chen Y, Huang W, Hou M, et al. The predictive value of urinary albumin-to-creatinine ratio for coronary artery abnormalities in Kawasaki
disease[J].Front Pediatr, 2025,13:1583603.
[19] Geng M, Zhang K. CRP-Albumin-Lymphocyte index (CALLYI) as a risk-predicting biomarker in association with osteoarthritis[J].Arthritis Res Ther, 2025,27(1):57.
[20] Pan Y, Liu Z, Tu R, et al. The value of the
CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in acute ischemic stroke[J].Sci Rep, 2025,15(1):13672.
[21] Saridas A, Çetinkaya R. The Prognostic value of the CALLY index in sepsis: a composite biomarker reflecting inflammation, nutrition, and immunity[J].Diagnostics (Basel), 2025,15(8):1026.
[22] Luo L, Li M, Xi Y, et al. C-reactive protein-albumin-lymphocyte index as a feasible nutrition-immunity-inflammation marker of the outcome of all-cause and cardiovascular mortality in elderly[J].Clin Nutr ESPEN, 2024,63:346-353.
[23] Han D, Wu L, Zhou H, et al. Associations of
the C-reactive protein-albumin-lymphocyte index with all-cause and
cardiovascular mortality among individuals with cardiovascular disease: evidence from the NHANES 2001-2010[J].BMC Cardiovasc Disord, 2025,25(1):144.
[24] Demir Y, Sevinc S. The prognostic value of C-reactive protein-albumin-lymphocyte (CALLY) index in predicting in-hospital
mortality after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI)[J].Catheter Cardiovasc Interv, 2025,106(2):1111-1118.
[25] 中华医学会儿科学分会心血管学组,中华医学会儿科学分会风湿学组,
中华医学会儿科学分会免疫学组.川崎病诊断和急性期治疗专家共识[J].中华儿科杂志,2022,60(1):6-13.
[26] Jia P, Shen F, Zhao Q, et al. Association between C-reactive protein-albumin-lymphocyte index and overall survival in patients with esophageal
cancer[J].Clin Nutr, 2025, 45:212-222.
[27] Duan Y, Wang T, Jia P, et al. Association between C-reactive protein-albumin-lymphocyte (CALLY) index with intravenous immunoglobulin non-response in Kawasaki disease[J].Ann Med, 2025,57(1):2548023.
[28] Psarakis G, Farmakis I, Zafeiropoulos S, et al. Predictive role of platelet-associated indices on admission and discharge in the long-term prognosis of acute coronary syndrome patients[J].Angiology, 2022,73(5):453-460.
[29] Wu Z, Fu L, Liu X, et al. The relationship
between C-reactive protein-albumin-lymphocyte index and peripheral artery disease[J].Sci Rep, 2025, 15(1):24380.
[30] Takeda Y, Sugano H, Okamoto T, et al. Prognostic usefulness of the C-reactive protein-albumin-lymphocyte (CALLY) index as a novel biomarker in patients undergoing colorectal cancer
surgery[J].Asian J Surg, 2024,47(8):3492-3498.
[31] Xu Z, Tang J, Xin C, et al. Associations of C-reactive
protein-albumin-lymphocyte (CALLY) index with cardiorenal syndrome: Insights from a population-based study[J].Heliyon, 2024,10(17):e37197.
[32] Ranasinghe RN, Biswas M, Vincent RP. Prealbumin: the clinical utility and analytical methodologies[J].Ann Clin Biochem, 2022,59(1):7-14.
[33] Shi M, Mao X, Wu X, et al. Serum prealbumin
levels and risks of adverse clinical outcomes after ischemic stroke[J].Clin Epidemiol, 2024,16:707-716.
[34] Pardo E, Jabaudon M, Godet T, et al. Dynamic assessment of prealbumin for nutrition support
effectiveness in critically ill patients[J].Clin Nutr, 2024, 43(6): 1343-1352.
|